Paolo Tarantino and Tess A. O'Meara
Jan 25, 2025, 16:19
Paolo Tarantino: Evolutions in the treatment of HER2+ breast cancer
Paolo Tarantino, Research fellow at Dana-Farber Cancer Institute, shared an article by Tess A. O’Meara on LinkedIn:
“Frontline treatment for HER2+ metastatic breast cancer has remained mostly unchanged for over a decade. Just to be revolutionized over one single year:
- First, the EMERALD trial at ASCO24, showing non-inferiority of an eribulin (vs taxane) backbone for HP.
- Then, PATINA, stunning the SABCS24 auditorium with the longest PFS ever seen for this disease, through the addition of palbociclib.
- And soon, DESTINY-Breast-09, with the highly anticipated substitution of first-line chemo with an ADC (T-DXd).
This all means huge opportunities for patients, but also relevant challenges to make the most adequate therapeutic choice in a rapidly evolving landscape.
In our latest JCO editorial, accompanying the brilliant EMERALD trial publication, Tess O’Meara, and I review these evolutions in the treatment of HER2+ breast cancer, suggesting a framework to select the most appropriate first-line treatment.
Read it here.”
Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study.
Authors: Tess A. O’Meara and Paolo Tarantino
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 25, 2025, 16:19
Jan 25, 2025, 15:49
Jan 25, 2025, 15:47
Jan 25, 2025, 15:41
Jan 25, 2025, 15:29
Jan 25, 2025, 15:23
Jan 25, 2025, 15:21
Jan 25, 2025, 15:20